Monday, September 12, 2016

BRIEF-FDA staff say neuropsychiatric risk with Pfizer's quit-smoking drug varies in studies, trial design has limitations

* Neuropsychiatric risk with Pfizer's quit-smoking drug

varies in studies, trial design has limitations & biases that

affect interpretation

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)